{"id":16247,"date":"2022-05-26T20:42:12","date_gmt":"2022-05-26T18:42:12","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=16247"},"modified":"2022-05-26T20:42:12","modified_gmt":"2022-05-26T18:42:12","slug":"janssen-annonce-lautorisation-de-mise-sur-le-marche-conditionnelle-pour-cartykti-ciltacabtagene-autoleucel-la-premiere-therapie-cellulaire-de-janssen-pour-le-traitement-des-patients-attein","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/janssen-annonce-lautorisation-de-mise-sur-le-marche-conditionnelle-pour-cartykti-ciltacabtagene-autoleucel-la-premiere-therapie-cellulaire-de-janssen-pour-le-traitement-des-patients-attein\/","title":{"rendered":"Janssen annonce l&#8217;autorisation de mise sur le march\u00e9 conditionnelle pour Cartykti\u00ae (Ciltacabtagene autoleucel), la premi\u00e8re th\u00e9rapie cellulaire de Janssen, pour le traitement des patients atteints d&#8217;une my\u00e9lome multiple en rechute et r\u00e9fractaire."},"content":{"rendered":"<p>L&#8217;autorisation a \u00e9t\u00e9 soutenue par l&#8217;\u00e9tude pivot CARTITUDE-1, incluant des patients qui avaient re\u00e7u une m\u00e9diane de six lignes de traitements ant\u00e9rieurs (intervalle, 3-18), et qui avaient pr\u00e9c\u00e9demment re\u00e7u un IMiD, un IP et un anticorps monoclonal anti-CD38. Les r\u00e9sultats pr\u00e9sent\u00e9s lors du congr\u00e8s annuel 2021 de l&#8217;<em>American Society of Clinical Oncology<\/em> (ASCO) ont montr\u00e9 qu&#8217;apr\u00e8s une dur\u00e9e m\u00e9diane de suivi de 18 mois (de 1,5 \u00e0 30,5 mois), un traitement par une dose unique de CARVYKTI\u00ae a entra\u00een\u00e9 des r\u00e9ponses profondes et durables de 98 % (intervalle de confiance [IC] de 95 %, 92,7-99. Notamment, 80 % des patients ont obtenu une r\u00e9ponse compl\u00e8te stringente (RCs), signifiant qu\u2019aucune maladie n\u2019est d\u00e9tectable par les m\u00e9thodes conventionnelles utilis\u00e9es en pratique clinique quotidiennes.<\/p>\n<p style=\"text-align: right;\"><em>D&#8217;apr\u00e8s un communiqu\u00e9 de presse de Janssen.<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>L&#8217;autorisation a \u00e9t\u00e9 soutenue par l&#8217;\u00e9tude pivot CARTITUDE-1, incluant des patients qui avaient re\u00e7u une m\u00e9diane de six lignes de traitements ant\u00e9rieurs (intervalle, 3-18), et qui avaient pr\u00e9c\u00e9demment re\u00e7u un [&hellip;]<\/p>","protected":false},"author":17,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[21],"tags":[],"ppma_author":[457],"class_list":["post-16247","post","type-post","status-publish","format-standard","hentry","category-communique-de-presse","author-pascale-raoul"],"aioseo_notices":[],"authors":[{"term_id":457,"user_id":17,"is_guest":0,"slug":"pascale-raoul","display_name":"Pascale Raoul","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/?s=96&d=mm&r=g","first_name":"","last_name":"","user_url":"","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16247","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=16247"}],"version-history":[{"count":0,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16247\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=16247"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=16247"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=16247"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=16247"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}